Critical  ||| S:0 E:9 ||| JJ
domains  ||| S:9 E:17 ||| NN
within  ||| S:17 E:24 ||| IN
the  ||| S:24 E:28 ||| DT
sequence  ||| S:28 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
human  ||| S:40 E:46 ||| JJ
organic  ||| S:46 E:54 ||| FW
anion  ||| S:54 E:60 ||| FW
transporting  ||| S:60 E:73 ||| FW
polypeptides  ||| S:73 E:86 ||| FW
Organic  ||| S:86 E:94 ||| FW
anion-transporting  ||| S:94 E:113 ||| FW
polypeptides  ||| S:113 E:126 ||| FW
( ||| S:126 E:127 ||| -LRB-
human  ||| S:127 E:133 ||| JJ
OATPs ||| S:133 E:138 ||| NN
;  ||| S:138 E:140 ||| :
other  ||| S:140 E:146 ||| JJ
species  ||| S:146 E:154 ||| JJ
Oatps ||| S:154 E:159 ||| NNP
;  ||| S:159 E:161 ||| :
gene  ||| S:161 E:166 ||| NN
family  ||| S:166 E:173 ||| NN
SLC21 ||| S:173 E:178 ||| NNP
/ ||| S:178 E:179 ||| NNP
SLCO ||| S:179 E:183 ||| NNP
)  ||| S:183 E:185 ||| -RRB-
play  ||| S:185 E:190 ||| VBP
important  ||| S:190 E:200 ||| JJ
roles  ||| S:200 E:206 ||| NNS
in  ||| S:206 E:209 ||| IN
drug  ||| S:209 E:214 ||| NN
absorption  ||| S:214 E:225 ||| NN
and  ||| S:225 E:229 ||| CC
distribution ||| S:229 E:241 ||| NN
.  ||| S:241 E:243 ||| .
In  ||| S:243 E:246 ||| IN
recent  ||| S:246 E:253 ||| JJ
years ||| S:253 E:258 ||| NNS
,  ||| S:258 E:260 ||| ,
much  ||| S:260 E:265 ||| JJ
information  ||| S:265 E:277 ||| NN
has  ||| S:277 E:281 ||| VBZ
been  ||| S:281 E:286 ||| VBN
obtained  ||| S:286 E:295 ||| VBN
on  ||| S:295 E:298 ||| IN
substrates  ||| S:298 E:309 ||| NNS
that  ||| S:309 E:314 ||| WDT
are  ||| S:314 E:318 ||| VBP
transported  ||| S:318 E:330 ||| VBN
by  ||| S:330 E:333 ||| IN
OATPs ||| S:333 E:338 ||| JJ
.  ||| S:338 E:340 ||| .
Computer-based  ||| S:340 E:355 ||| JJ
hydropathy  ||| S:355 E:366 ||| JJ
analysis  ||| S:366 E:375 ||| NN
predicts  ||| S:375 E:384 ||| VBZ
that  ||| S:384 E:389 ||| IN
OATP  ||| S:389 E:394 ||| NNP
family  ||| S:394 E:401 ||| NN
members  ||| S:401 E:409 ||| NNS
share  ||| S:409 E:415 ||| VBP
several  ||| S:415 E:423 ||| JJ
structural  ||| S:423 E:434 ||| JJ
features  ||| S:434 E:443 ||| NNS
including  ||| S:443 E:453 ||| VBG
twelve  ||| S:453 E:460 ||| JJ
transmembrane  ||| S:460 E:474 ||| JJ
domains  ||| S:474 E:482 ||| NNS
( ||| S:482 E:483 ||| -LRB-
TMs ||| S:483 E:486 ||| NNP
) ||| S:486 E:487 ||| -RRB-
,  ||| S:487 E:489 ||| ,
conserved  ||| S:489 E:499 ||| JJ
cysteine  ||| S:499 E:508 ||| JJ
residues  ||| S:508 E:517 ||| NNS
at  ||| S:517 E:520 ||| IN
extracellular  ||| S:520 E:534 ||| CD
loop  ||| S:534 E:539 ||| CD
5 ||| S:539 E:540 ||| CD
,  ||| S:540 E:542 ||| ,
glycosylation  ||| S:542 E:556 ||| JJ
sites ||| S:556 E:561 ||| NNS
,  ||| S:561 E:563 ||| ,
PDZ  ||| S:563 E:567 ||| NNP
binding  ||| S:567 E:575 ||| JJ
domains  ||| S:575 E:583 ||| NN
as  ||| S:583 E:586 ||| IN
well  ||| S:586 E:591 ||| RB
as  ||| S:591 E:594 ||| IN
putative  ||| S:594 E:603 ||| JJ
phosphorylation  ||| S:603 E:619 ||| JJ
sites ||| S:619 E:624 ||| NNS
.  ||| S:624 E:626 ||| .
Studies  ||| S:626 E:634 ||| NNS
on  ||| S:634 E:637 ||| IN
transmembrane  ||| S:637 E:651 ||| JJ
domains  ||| S:651 E:659 ||| NNS
have  ||| S:659 E:664 ||| VBP
identified  ||| S:664 E:675 ||| VBN
several  ||| S:675 E:683 ||| JJ
amino  ||| S:683 E:689 ||| JJ
acids  ||| S:689 E:695 ||| NNS
that  ||| S:695 E:700 ||| WDT
are  ||| S:700 E:704 ||| VBP
essential  ||| S:704 E:714 ||| JJ
for  ||| S:714 E:718 ||| IN
substrate  ||| S:718 E:728 ||| JJ
uptake ||| S:728 E:734 ||| NN
;  ||| S:734 E:736 ||| :
while  ||| S:736 E:742 ||| IN
mutation  ||| S:742 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
the  ||| S:754 E:758 ||| DT
conserved  ||| S:758 E:768 ||| JJ
cysteine  ||| S:768 E:777 ||| JJ
residues  ||| S:777 E:786 ||| NNS
and  ||| S:786 E:790 ||| CC
glycosylation  ||| S:790 E:804 ||| JJ
sites  ||| S:804 E:810 ||| NNS
resulted  ||| S:810 E:819 ||| VBD
in  ||| S:819 E:822 ||| IN
mis-processing  ||| S:822 E:837 ||| JJ
transporter  ||| S:837 E:849 ||| NN
proteins ||| S:849 E:857 ||| NNS
.  ||| S:857 E:859 ||| .
The  ||| S:859 E:863 ||| DT
interaction  ||| S:863 E:875 ||| NN
with  ||| S:875 E:880 ||| IN
PDZ  ||| S:880 E:884 ||| NNP
proteins  ||| S:884 E:893 ||| NNS
and  ||| S:893 E:897 ||| CC
phosphorylation  ||| S:897 E:913 ||| JJ
modification  ||| S:913 E:926 ||| NN
of  ||| S:926 E:929 ||| IN
OATPs ||| S:929 E:934 ||| NNP
,  ||| S:934 E:936 ||| ,
on  ||| S:936 E:939 ||| IN
the  ||| S:939 E:943 ||| DT
other  ||| S:943 E:949 ||| JJ
hand ||| S:949 E:953 ||| NN
,  ||| S:953 E:955 ||| ,
mainly  ||| S:955 E:962 ||| RB
regulate  ||| S:962 E:971 ||| VB
the  ||| S:971 E:975 ||| DT
trafficking  ||| S:975 E:987 ||| NN
of  ||| S:987 E:990 ||| IN
these  ||| S:990 E:996 ||| DT
transporters ||| S:996 E:1008 ||| NN
.  ||| S:1008 E:1010 ||| .
Although  ||| S:1010 E:1019 ||| IN
progress  ||| S:1019 E:1028 ||| NN
has  ||| S:1028 E:1032 ||| VBZ
been  ||| S:1032 E:1037 ||| VBN
made  ||| S:1037 E:1042 ||| VBN
on  ||| S:1042 E:1045 ||| IN
revealing  ||| S:1045 E:1055 ||| VBG
the  ||| S:1055 E:1059 ||| DT
critical  ||| S:1059 E:1068 ||| JJ
domains  ||| S:1068 E:1076 ||| NN
of  ||| S:1076 E:1079 ||| IN
OATPs ||| S:1079 E:1084 ||| NNP
,  ||| S:1084 E:1086 ||| ,
information  ||| S:1086 E:1098 ||| NN
is  ||| S:1098 E:1101 ||| VBZ
still  ||| S:1101 E:1107 ||| RB
limited  ||| S:1107 E:1115 ||| VBN
and  ||| S:1115 E:1119 ||| CC
more  ||| S:1119 E:1124 ||| JJR
studies  ||| S:1124 E:1132 ||| NNS
on  ||| S:1132 E:1135 ||| IN
these  ||| S:1135 E:1141 ||| DT
aspects  ||| S:1141 E:1149 ||| NNS
are  ||| S:1149 E:1153 ||| VBP
needed ||| S:1153 E:1159 ||| VBN
.  ||| S:1159 E:1161 ||| .
A  ||| S:1161 E:1163 ||| DT
better  ||| S:1163 E:1170 ||| JJR
understanding  ||| S:1170 E:1184 ||| NN
of  ||| S:1184 E:1187 ||| IN
the  ||| S:1187 E:1191 ||| DT
important  ||| S:1191 E:1201 ||| JJ
structural  ||| S:1201 E:1212 ||| JJ
domains  ||| S:1212 E:1220 ||| NN
of  ||| S:1220 E:1223 ||| IN
OATPs  ||| S:1223 E:1229 ||| NNP
will  ||| S:1229 E:1234 ||| MD
shed  ||| S:1234 E:1239 ||| VB
light  ||| S:1239 E:1245 ||| NN
on  ||| S:1245 E:1248 ||| IN
future  ||| S:1248 E:1255 ||| JJ
targeted  ||| S:1255 E:1264 ||| JJ
drug  ||| S:1264 E:1269 ||| NN
design  ||| S:1269 E:1276 ||| NN
and  ||| S:1276 E:1280 ||| CC
a  ||| S:1280 E:1282 ||| DT
more  ||| S:1282 E:1287 ||| RBR
in-depth  ||| S:1287 E:1296 ||| JJ
analysis  ||| S:1296 E:1305 ||| NN
of  ||| S:1305 E:1308 ||| IN
inter-individual  ||| S:1308 E:1325 ||| JJ
variability  ||| S:1325 E:1337 ||| NN
of  ||| S:1337 E:1340 ||| IN
drug  ||| S:1340 E:1345 ||| NN
disposition ||| S:1345 E:1356 ||| NN
.  ||| S:1356 E:1358 ||| .
